Page 67 - IJB-8-4
P. 67

Fang, et al.
           Author contributions                                    Tumor-on-a-chip  Platform  to  Study  Tumor-Stroma

           Supervision: Weiqing Wan                                Interactions and Drug Pharmacokinetics. Adv Healthc Mater,
           Conceptualization: Lingling Fang, Weiqing Wan           9:2000880.
           Investigation: Lingling Fang, Yu Liu, Junfeng Qiu       https://doi.org/10.1002/adhm.202000880
           Methodology: Lingling Fang, Yu Liu                  11.  He Y, Nie J, Xie M, et al., 2020, Why Choose 3D Printing?
           Formal analysis: Junfeng Qiu                            Part III: Printing in 3D Models for Drug Screening. Bio Des
           Visualization: Junfeng Qiu                              Manufac, 3:160–3.
           Writing – original draft: Lingling Fang, Yu Liu         https://doi.org/10.1007/s42242-020-00067-7
           Writing – review and editing: Lingling Fang, Weiqing Wan
                                                               12.  Samadian H, Jafari S, Sepand MR, et al., 2021, 3D Bioprinting
            References                                             Technology to Mimic the Tumor Microenvironment: Tumor-
                                                                   on-a-chip Concept. Mat Today Adv, 12:100160.
           1.   Bray F, Ferlay J, Soerjomataram I, et al., 2018, Global Cancer      https://doi.org/10.1016/j.mtadv.2021.100160
               Statistics  2018: GLOBOCAN  Estimates of Incidence  and   13.  Cao X, Ashfaq R, Cheng F, et al., 2019, A Tumor-on-a-chip
               Mortality Worldwide for 36 Cancers in 185 Countries. CA   System with Bioprinted Blood AND Lymphatic Vessel Pair.
               Cancer J Clin, 68:394–424.                          Adv Funct Mater, 29:1807173.
               https://doi.org/10.3322/caac.21492                  https://doi.org/10.1002/adfm.201807173
           2.   Sung H, Ferlay  J, Siegel  RL,  et al., 2021, Global Cancer   14.  Radhakrishnan J,  Varadaraj  S, Dash SK,  et al., 2020,
               Statistics  2020: GLOBACAN  Estimates of Incidence  and   Organotypic Cancer Tissue Models for Drug Screening: 3D
               Mortality Worldwide for 36 Cancers in 185 Countries. CA   Constructs, Bioprinting and Microfluidic Chips. Drug Discov
               Cancer J Clin, 71:209–49.                           Today, 25:879–90.
               https://doi.org/10.3322/caac.21660                  https://doi.org/10.1016/j.drudis.2020.03.002
           3.   Ferlay J, Colombet M, Soerjomataram I, et al., 2018, Cancer   15.  Mak IW, Evaniew  N, Ghert M, 2014, Lost in Translation:
               Incidence  and Mortality  Patterns in Europe: Estimates  for   Animal Models and Clinical Trials in Cancer Treatment. Am
               40 Countries and 25 Major Cancers in 2018. Eur J Cancer,   J Transl Res, 6:114–8.
               103:356–87.                                     16.  Kronemberger GS, Miranda GA, Tavares RS, et al., 2021,
               https://doi.org/10.1016/j.ejca.2018.07.005          Recapitulating  Tumorigenesis  In Vitro: Opportunities and
           4.   Stewart B, Wild CP, 2014, World Cancer Report 2014. IARC   Challenges of 3D Bioprinting.  Front Bioeng Biotechnol,
               Publication.                                        9:682498.
           5.   Knowlton  S,  Onal  S, Yu  CH,  et  al.,  2015,  Bioprinting  for      https://doi.org/10.3389/fbioe.2021.682498
               Cancer Research. Trends Biote, 33:504–13.       17.  Nath S, Devi GR, 2016, Three-Dimensional Culture Systems
           6.   Hay M,  Thomas DW, Craighead JL,  et al., 2014, Clinical   in Cancer Research: Focus on  Tumor Spheroid Model.
               Development Success Rates for Investigational Drugs. Nat   Pharmacol Therap, 163:94–108.
               Biotechnol, 32:40–51.                               https://doi.org/10.1016/j.pharmthera.2016.03.013
               https://doi.org/10.1038/nbt.2786                18.  Zaeri A, Cao K, Zhang F, et al., 2022, A Review of the Structural
           7.   Smietana  K, Siatkowski M, Møller M, 2016,  Trends in   and Physical Properties that Govern Cell Interactions  with
               Clinical Success Rates. Nat Rev Drug Discov, 15:379.  Structured Biomaterials Enabled by Additive Manufacturing.
               https://doi.org/10.1038/nrd.2016.85                 Bioprinting, 26:e00201.
           8.   Heylman C, Sobrino A, Shirure VS, et al., 2014, A strategy for      https://doi.org/10.1016/j.bprint.2022.e00201
               integrating  essential  three-dimensional  microphysiological   19.  Augustine R, Kalva SN, Ahmad R, et al., 2021, 3D Bioprinted
               systems of human organs for realistic  anticancer  drug   Cancer  Models: Revolutionizing Personalized  Cancer
               screening. Exp Biol Med (Maywood), 239:1240–54.     Therapy. Trans Oncol, 14:101015.
               https://doi.org/10.1177/1535370214525295            https://doi.org/10.1016/j.tranon.2021.101015
           9.   Imamura Y, Mukohara T, Shimono Y, et al., 2015, Comparison   20.  Lopatina T, Gai C, Deregibus MC, et al., 2016, Cross Talk
               of 2D- and 3D-Culture Models as Drug-Testing Platforms in   Between Cancer and Mesenchymal Stem Cells  Through
               Breast Cancer. Oncol Rep, 33:1837–43.               Extracellular Vesicles Carrying Nucleic Acids. Front Oncol,
               https://doi.org/10.3892/or.2015.3767                6:239.
           10.  Chi CW, Lao YH, Ahmed R, et al., 2020, High-Throughput      https://doi.org/10.3389/fonc.2016.00125

                                       International Journal of Bioprinting (2022)–Volume 8, Issue 4        59
   62   63   64   65   66   67   68   69   70   71   72